Study on protective effects and its mechanism of leflunomide on renal tissue in rat IgA nephropathy model

Chinese Critical Care Medicine

Volumn 20, Issue 5, 2008, Pages 283-286

  Tang, Ying ^a   Lou, Tan Qi ^a   Wang, Cheng ^a   Peng, Hui ^a   Liu, Xun ^a   Tang, Hua ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Experimental IgA nephropathy; Leflunomide; Monocyte chemotaxis peptide1; Transforming growth factor 1

Indexed keywords

LEFLUNOMIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; PREDNISONE; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN ANTIBODY COMPLEX; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; GENE EXPRESSION; HISTOPATHOLOGY; HYPERPLASIA; IMMUNOFLUORESCENCE; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOHISTOCHEMISTRY; KIDNEY FIBROSIS; MESANGIUM; MICROSCOPY; NONHUMAN; PROTEIN EXPRESSION; RAT; RENAL PROTECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; CHEMOKINE CCL2; DISEASE MODELS, ANIMAL; FIBROSIS; GLOMERULONEPHRITIS, IGA; ISOXAZOLES; KIDNEY; MALE; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; TRANSFORMING GROWTH FACTOR BETA1;

EID: 44649091954     PISSN: 10030603     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Abe A, Utsunomiya Y. The role of the interaction between macrophages and mesangial cells in the progression of IgA nephropathy[J]. Nippon Jinzo Gakkai Shi,1996,38(11):519-529.
2. Wada J, Sugiyama H, Makino H. Pathogenesis of IgA nephropathy[J]. Semin Nephrol,2003,23(6):556-563.
3. Ou Z L, Hotta O, Natori Y, et al. Enhanced expression of C chemokine lymphotactin in IgA nephropathy [J]. Nephron, 2002,91(2):262-269.
4. Fukasawa H, Yamamoto T, Suzuki H, et al. Treatment with anti-TGF-beta antibody ameliorates chronic progressive nephritis by inhibiting Smad/ TGF-beta signaling [J]. Kidney Int,2004,65(1):63-74.
5. Ihm C G, Park J K, Hong S P, et al. A high glucose concentration stimulates the expression of monocyte chemotactic peptidel in human mesangial cells[J]. Nephron,1998,79(1): 33-37.
6. Hardinger K L, Wang C D, Schnitzler M A, et al. Prospective, pilot, open-label, short-term study of conversion to leflunomide reverses chronic renal allograft dysfunction [J]. Am J Transplant,2002,2(9):867-871.
7. Remer C F, Weisman M H, Wallace D J. Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study[J]. Lupus,2001,10(7):480-483.
8. Chinese source.
9. Chinese source.
10. Lai K N. Future directions in the treatment of IgA nephropathy[J]. Nephron,2002,92(2):263-270.
11. Davis J P, Cain G A, Pitts W J, et al. The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase[J]. Biochemistry,1996,35(4): 1270-1273.
12. Breedveld F C, Dayer F C. Leflunomide: mode of action in the treatment of rheumatoid arthritis[J]. Ann Rheum Dis,2000, 59(5):841-849.
13. Kraan M C, Reece R J, Barg E C, et al. Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis, findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers[J]. Arthritis Rheum,2000,43(8):1820-1830.
14. Chinese source.
15. Chinese source.
16. Chinese source.
17. Chinese source.
18. Chinese source.
19. Yang C W, Hsueh S, Wu M S, et al. Glomerular transforming growth factor-beta1 mRNA as a marker of glomerulosclerosis-application in renal biopsies[J]. Nephron,1997,77 (3):290-297.